文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

口服依他佐辛治疗难治性抑郁症患者体验的现象学和治疗潜力:诠释现象学研究。

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.

机构信息

Department of Psychiatry, Research School of Behavioural and Cognitive Neurosciences (BCN), University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700, RB, Groningen, the Netherlands.

Department of Care Ethics, University of Humanistic Studies, Utrecht, The Netherlands.

出版信息

Psychopharmacology (Berl). 2023 Jul;240(7):1547-1560. doi: 10.1007/s00213-023-06388-6. Epub 2023 May 24.


DOI:10.1007/s00213-023-06388-6
PMID:37222753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10271905/
Abstract

BACKGROUND: Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression. The phenomenology of ketamine-induced experiences and their relation to its psychotherapeutic potential have not yet been systematically investigated. AIMS: To describe the phenomenology of patient experiences during oral esketamine treatment for treatment-resistant depression (TRD) and to explore the potential therapeutic relevance of these experiences. METHODS: In-depth interviews were conducted with 17 patients after a 6-week, twice-weekly 'off label' generic oral esketamine (0.5-3.0mg/kg) treatment program. Interviews explored participants' perspectives, expectations, and experiences with oral esketamine treatment. Audio interviews were transcribed and analyzed using an Interpretative Phenomenological Analysis (IPA) framework. RESULTS: The effects of ketamine were highly variable, and psychological distress was common in most patients. Key themes included (a) perceptual effects (auditory, visual, proprioceptive), (b) detachment (from body, self, emotions, and the world), (c) stillness and openness, (d) mystical-type effects (transcendence, relativeness, spirituality), and (e) fear and anxiety. Key themes related to post-session reports included (a) feeling hungover and fatigued, and (b) lifting the blanket: neutralizing mood effects. CONCLUSION: Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences. These experiences deserve to be explored further to enhance treatment outcomes in patients with TRD. Given the frequency and severity of the perceived distress, we identify a need for additional support in all stages of esketamine treatment.

摘要

背景:氯胺酮及其对映体被广泛研究,并越来越多地用于治疗精神障碍,尤其是治疗抵抗性抑郁症。氯胺酮引起的体验的现象学及其与心理治疗潜力的关系尚未得到系统研究。

目的:描述接受口服氯胺酮治疗治疗抵抗性抑郁症(TRD)的患者的体验现象学,并探讨这些体验的潜在治疗相关性。

方法:对 17 名接受为期 6 周、每两周一次的“标签外”通用口服氯胺酮(0.5-3.0mg/kg)治疗方案的患者进行深入访谈。访谈探讨了参与者对口服氯胺酮治疗的看法、期望和体验。使用解释性现象学分析(IPA)框架对音频访谈进行转录和分析。

结果:氯胺酮的效果高度可变,大多数患者都有心理困扰。主要主题包括(a)知觉效应(听觉、视觉、本体感觉),(b)分离(身体、自我、情绪和世界),(c)静止和开放,(d)神秘型效应(超越、相对性、灵性),和(e)恐惧和焦虑。与治疗后报告相关的主要主题包括(a)感觉宿醉和疲劳,和(b)掀起毯子:中和情绪效应。

结论:患者报告了几种具有心理治疗潜力的氯胺酮效应,例如增加开放性、分离性、中断负面性和神秘型体验。这些体验值得进一步探索,以提高 TRD 患者的治疗效果。鉴于感知到的痛苦的频率和严重程度,我们认为需要在氯胺酮治疗的所有阶段提供额外的支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8b7/10271905/6a9941ae7a1d/213_2023_6388_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8b7/10271905/6a9941ae7a1d/213_2023_6388_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8b7/10271905/6a9941ae7a1d/213_2023_6388_Fig1_HTML.jpg

相似文献

[1]
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.

Psychopharmacology (Berl). 2023-7

[2]
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study.

Front Psychiatry. 2022-11-25

[3]
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.

J Affect Disord. 2021-10-1

[4]
Esketamine for treatment resistant depression.

Expert Rev Neurother. 2019-10

[5]
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.

Int J Neuropsychopharmacol. 2020-7-29

[6]
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.

BMC Psychiatry. 2021-10-25

[7]
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.

J Affect Disord. 2020-3-1

[8]
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

Eur Neuropsychopharmacol. 2023-5

[9]
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

Am J Psychiatry. 2019-5-21

[10]
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.

J Psychopharmacol. 2021-2

引用本文的文献

[1]
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).

J Pers Med. 2025-4-21

[2]
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.

Int J Ment Health Nurs. 2025-2

[3]
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.

J Affect Disord. 2024-9-15

[4]
Enhancing Agency in Posttraumatic Stress Disorder Therapies Through Sensorimotor Technologies.

J Med Internet Res. 2024-7-1

[5]
Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.

Psychedelic Med (New Rochelle). 2023-12-1

[6]
Overcoming the myths of esketamine administration: different and not difficult.

Front Psychiatry. 2023-11-23

[7]
The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.

Brain Sci. 2023-10-22

本文引用的文献

[1]
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.

J Affect Disord. 2023-2-15

[2]
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.

J Psychopharmacol. 2022-10

[3]
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.

Psychopharmacology (Berl). 2022-11

[4]
Active mechanisms of ketamine-assisted psychotherapy: A systematic review.

J Affect Disord. 2022-10-15

[5]
The conundrum of therapeutic intoxication.

Br J Psychiatry. 2022-8

[6]
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

J Pain Res. 2022-6-15

[7]
Toward Synergies of Ketamine and Psychotherapy.

Front Psychol. 2022-3-25

[8]
Ketamine Analgesia and Psychedelia: Can We Dissociate Dissociation?

Anesthesiology. 2022-5-1

[9]
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.

Int J Neuropsychopharmacol. 2022-4-19

[10]
Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.

Am J Psychiatry. 2022-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索